Pharma & Bio
Lifestyle
Investor Sentiment Returns… Focus on Inflection Points for HLB INC., VUNO, and BNC KOREA [Bio Spotlight]
On the 28th, the pharmaceutical, biotech, and medical device (bio) sectors—led by HLB Group—were the driving force behind the KOSDAQ market’s rebound. Breaking through macroeconomic uncertainty and a …
Technology
The Path for “Once-a-Month Weight-Loss Drugs” Widens… Viking’s Success Puts Korean Long-Acting Drug Industry on Edge
U.S.-based Viking Therapeutics has proposed the possibility of a once-monthly weight-loss drug without the need for a separate long-acting formulation technology. From the perspective of domestic deve…
Technology
Next-Generation Osteoarthritis Treatment Emerges as a Rising Star... Kim Dae-won, CEO of ICM: "We’ve Addressed Both Structural Issues and Pain"
“For osteoarthritis treatments, simply reducing pain is not enough. They must also restore damaged joint structures, reduce inflammation, and demonstrate that patients actually experience less pain an…
Lifestyle
Vaxcell-Bio Therapeutics: Why It Filed for a ‘Clinical Trial’ Despite Risk Adjustments for VCB-1102
Vaxcell-Bio Therapeutics(323990)is launching additional clinical trials, including a controlled study, to enter the market for the treatment of advanced liver cancer with its core pipeline product, th…
Technology
RNA Editing Heats Up: Why Are Anticancer Drugs So Rare?…Rznomics Inc.’s Indirect Strategy
The global competition for new RNA-editing drugs is now fully entering the clinical trial phase. However, major companies’ development efforts remain focused on rare and genetic diseases. This is why …
Technology
Proteina Rises on AI Data...Ingenia Advances to Phase 3 [K-Bio Pulse]
South Korea’s pharmaceutical and life sciences sectors moved in opposite directions on Sept. 23. The life sciences sector rose 0.64%, while the pharmaceutical sector fell 0.45%.
(Graphic by ChatGPT…
Lifestyle
PROTEINA CO., LTD. Benefits from AI-Driven New Drug Development… Ingenia Highlights the Technological Value of Its Global Phase 3 Trial [Bio Spotlight]
On the 23rd, the domestic pharmaceutical and life sciences sectors showed mixed trends. The life sciences sector rose 0.64%. Of the 92 stocks in the sector, 53 rose, 8 remained unchanged, and 31 fell,…
Technology
Graphy Chairman Outlines Ray Strategy and Relationship with MegaGen
Graphy has defined its relationship with MegaGen Implant, or MegaGen, primarily as a business partnership following its acquisition of management control of Ray.Although MegaGen holds a 7.69% stake in…
Technology
[Exclusive] Graphy Inc., Backed by Ray Co., Ltd.… CEO Shim Un-seop: “Business Cooperation with Megagen, Not a Battle for Control”
#Graphy Inc., which acquired management control of Ray Co., Ltd.(228670), announced that it has no plans to seek a seat on the board of Megagen Implant (hereinafter “Megagen”), the second-largest shar…
Technology
FDA Approval Is Just the Beginning… What Is HLB INC.’s Strategy to Break Into the Niche Market for Intrahepatic Bile Duct Cancer with ‘Ripictu’?
While HLB INC.(028300)has successfully obtained U.S. Food and Drug Administration (FDA) approval for “Ripicto” (active ingredient: lirapugratinib), a new drug for cholangiocarcinoma, analysts say that…